Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas

Volm, M; Drings, P.; Wodrich, W

doi:10.1007/bf01686458

Cited by 70 publications

(35 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Investigations focussing on abnormalities of oncogenes (e.g. Ki-ras, c-fos, c-jun and c-erb B1) and tumor suppressor genes (p53, Rb), especially in primary tissues of NSCLC, are still limited (Rodenhuis et al, 1987(Rodenhuis et al, , 1988Slebos et al, 1990;Volm et al, 1993;Bongiorno et al, 1994;Takahashi et al, 1989;Harbour et al, 1988). Various members of the family of protein kinases are involved in the development of human neoplasms, but the knowledge of their role in primary NSCLC is also restricted (Bishop et al, 1991;Strebhardt et al, 1994).…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer

et al. 1997

View full text Add to dashboard Cite

Our previous data indicate that the expression of the PLK gene which codes for a serine/threonine kinase is restricted to proliferating cells. In Northern blot experiments PLK mRNA expression was at the limit of detection in normal lung tissue but elevated in most samples of non-small cell lung cancer (NSCLC). A very low frequency of PLK transcripts was only found in bronchiolo-alveolar carcinomas. NSCLC patients whose tumors showed moderate PLK expression survived signi®cantly longer (5 year survival rate=51.8%) than those with high levels of PLK transcripts (24.2%, P=0.001). No statistically signi®cant correlation was found between PLK mRNA expression and age, sex, TNM status, histological type or degree of dierentiation. Interestingly, the prognosis of patients in postsurgical stages I and II was correlated with PLK expression (5 year survival rates in stage I: 69.1% (moderate PLK) ± 43.5% (high PLK), P=0.03 or in stage II: 51.9% (moderate PLK) ± 9.9% (high PLK), P=0.006). These results suggest that PLK mRNA expression provides a new independent prognostic indicator for patients with NSCLC.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer

et al. 1997

View full text Add to dashboard Cite

show abstract

“…Another unsolved problem is the association between HER2 status and prognosis in lung cancer patients. Overexpression of the HER2 protein is associated with shorter survival in some, 1,5,16 but not all, 4,6,17,18 reports. Overexpression of p185 HER2 was evaluated by IHC in those studies.…”

mentioning

confidence: 99%

Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non‐small cell lung cancer

Nakamura

Saji

Ogata

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

The HER2 oncogene, which encodes the tyrosine kinase receptor, is commonly overexpressed in several types of cancer. Treatment using a humanized monoclonal antibody bound to HER2 product is becoming standard therapy for advanced breast cancer. Overexpression occurs in approximately 30% of non-small cell lung cancers (NSCLCs) and has been associated with poor prognosis. However, the frequency of a genetic aberration in the HER2 gene in lung cancer and the association between gene amplification and prognosis are poorly defined. To clarify these relationships, we simultaneously analyzed protein overexpression by immunohistochemistry (IHC) and determined the gene copy number by FISH in 50 surgical specimens of NSCLC. A lowgrade increase in the copy number (3 to 8 copies) of the HER2 gene was detected in 44% of tumors. Most represented polysomy of chromosome 17. Protein overexpression was observed in 26%. Overexpression was detected in adenocarcinoma more frequently than in squamous cell carcinoma. No significant correlation was observed between copy number increase and overexpression. Neither gene copy number increase nor overexpression correlated with survival. We conclude that the significance of HER2 status in NSCLC is different from that in breast cancer because high-grade amplification occurs rarely.

show abstract

“…Immunohistochemical studies have reported EGFR overexpression in 22 -81% of NSCLC tumours depending on the antibody used and cut point that defines overexpression (Veale et al, 1987;Volm et al, 1993;Pfeiffer et al, 1996;Cornianu and Tudose, 1997;Pastorino et al, 1997;Rusch et al, 1997;Fontanini et al, 1998;Greatens et al, 1998;D'Amico et al, 1999;Fu et al, 1999;Cox et al, 2000;Ohsaki et al, 2000;Selvaggi et al, 2002;Hirsch et al, 2003;Kanematsu et al, 2003;Mukohara et al, 2003;Onn et al, 2003). The majority of these studies have failed to demonstrate an association with prognosis (Table 1).…”

mentioning

confidence: 99%

Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer

2004

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR) is commonly expressed in non-small-cell lung cancer (NSCLC) and promotes a host of mechanisms involved in tumorigenesis. However, EGFR expression does not reliably predict prognosis or response to EGFR-targeted therapies. The data from two previous studies of a series of 181 consecutive surgically resected stage I -IIIA NSCLC patients who had survived in excess of 60 days were explored. Of these patients, tissue was available for evaluation of EGFR in 179 patients, carbonic anhydrase (CA) IX in 177 patients and matrix metalloproteinase-9 (MMP-9) in 169 patients. We have previously reported an association between EGFR expression and MMP-9 expression. We have also reported that MMP-9 (P ¼ 0.001) and perinuclear (p)CA IX (P ¼ 0.03) but not EGFR expression were associated with a poor prognosis. Perinuclear CA IX expression was also associated with EGFR expression (Po0.001). Multivariate analysis demonstrated that coexpression of MMP-9 with EGFR conferred a worse prognosis than the expression of MMP-9 alone (Po0.001) and coexpression of EGFR and pCA IX conferred a worse prognosis than pCA IX alone (P ¼ 0.05). A model was then developed where the study population was divided into three groups: group 1 had expression of EGFR without coexpression of MMP-9 or pCA IX (number ¼ 21); group 2 had no expression of EGFR (number ¼ 75); and group 3 had coexpression of EGFR with pCA IX or MMP-9 or both (number ¼ 70). Group 3 had a worse prognosis than either groups 1 or 2 (P ¼ 0.0003 and 0.027, respectively) and group 1 had a better prognosis than group 2 (P ¼ 0.036). These data identify two cohorts of EGFR-positive patients with diametrically opposite prognoses. The group expressing either EGFR and or both MMP-9 and pCA IX may identify a group of patients with activated EGFR, which is of clinical relevance with the advent of EGFR-targeted therapies.

show abstract

Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas

Cited by 70 publications

References 14 publications

Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer

Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer

Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non‐small cell lung cancer

Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer

Contact Info

Product

Resources

About